Bellus Health Inc. is a clinical-stage biopharmaceutical company based in Laval, Canada, that focuses on developing therapeutics for chronic cough and other hypersensitization disorders. Its lead drug candidate, BLU-5937, is an oral small molecule antagonist of the P2X3 receptor, currently undergoing Phase II clinical trials for chronic cough and chronic pruritus. The company is also engaged in developing KIACTA™, a treatment for AA amyloidosis, a rare kidney disease, which has completed its Phase 3 study. KIACTA™ is also being explored for sarcoidosis, a serious inflammatory condition affecting the lungs. Additionally, Bellus Health is working on Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli, with pre-clinical studies underway. The company has a pipeline that includes research on AL amyloidosis, where amyloid protein accumulation leads to organ dysfunction.